Between Groundhog Day’s prediction for 6 more weeks of winter and the recent cold fronts rushing into both northern and southern states, wintery weather may linger this year – and with it, the chance ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for ...

This approach could have a significant impact on the bovine industry in the U.S. and globally as IVF is an increasingly popular method for breeding ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery ...

Although the 65 patients in the aPTT group received more heparin than the 66 patients in ... and therapeutic in the aPTT group, there were no significant differences in recurrent venous ...

Injecting tenecteplase into the artery after clot removal helps improve recovery in stroke survivors, leading to better ...

Disability was measured by a score of 0-1 on the modified Rankin Scale with ratings from 0 (no disability) to 6 (death). The analysis found: Stroke survivors were 44% more likely to have an ...

LOS ANGELES -- For patients with large vessel occlusion (LVO) strokes, researchers found ways to make adjunctive ...

Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and ...

Early findings suggest that IA tenecteplase after successful thrombectomy is safe and improves functional outcomes over standard care in anterior circulation LVO stroke.

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...